Jian Li

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · The Lancet Oncology · 2017 · 520 citations

Medicine, Pathology, Gefitinib Versus Vinorelbine +8

Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)

Chengqiang Li, Shengguang Zhao, Yuyan Zheng et al. · European Journal of Cancer · 2020 · 303 citations

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +6

Near-infrared emissive carbon dots with 33.96% emission in aqueous solution for cellular sensing and light-emitting diodes

Boyang Wang, Jian Li, Zhiyong Tang et al. · Science Bulletin · 2019 · 290 citations · Full text

Engineering, Carbon-based Material, Nanomaterials +8

Temporal Dissection of Tumorigenesis in Primary Cancers

Steffen Durinck, Christine Ho, Nicholas J. Wang et al. · Cancer Discovery · 2011 · 267 citations · Full text

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · Journal of Clinical Oncology · 2020 · 261 citations · Full text